Optimizing Immune-related Tumor Response Assessment: Does Reducing the Number of Lesions Impact Response Assessment in Melanoma Patients Treated with Ipilimumab?

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2014 Jul 4

PMID 24991412

Citations 42

Authors

Mizuki Nishino

Maria Gargano

Margaret Suda

Nikhil H Ramaiya

F Stephen Hodi

Affiliations

Soon will be listed here.

Abstract

Background: Investigate the impact of the reduction of the number of target lesions on immune-related response assessment in advanced melanoma patients treated with ipilimumab.

Method: Ninety patients (53 males, 37 females; age range: 25-87) with advanced melanoma treated with ipilimumab in two clinical trials were studied. Tumor measurements during trial allowing up to 5 lesions per organ and 10 lesions in total were retrospectively reviewed. A second set of tumor measurements allowing up to 2 lesions per organ and 5 lesions in total was generated. Immune-related response assessments by two measurements were compared.

Results: The number of target lesions was significantly reduced when up to 2 per organ and 5 in total lesions were allowed (Wilcoxon P < 0.0001). The immune-related response assessment using reduced number of lesions was highly concordant with assessment using the original number of lesions (Spearman r for the percent change on 1(st)-3(rd) follow-up: 0.860-0.970; κw for best immune-related response: 0.908). Median time-to-progression was 26.9 months (95%CI: 9.1-∞) by both assessments. Interobserver agreement of measurements was high for both assessments, with the concordance correlation coefficient above 0.98.

Conclusion: Reduction of the number of target lesions did not significantly affect immune-related response assessment or the measurement variability in advanced melanoma patients treated with ipilimumab. Using up to 2 per organ and 5 in total target lesions is proposed to assess immune-related response, while it is important to keep other novel features of immune-related response criteria such as confirmation of progression and inclusion of new lesion measurements.

Citing Articles

Assessing Radiological Response to Immunotherapy in Lung Cancer: An Evolving Arena.

Rallis K, Makker S, Ghose A, Sideris M Cancer Diagn Progn. 2024; 4(1):1-8.

PMID: 38173660 PMC: 10758839. DOI: 10.21873/cdp.10278.

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.

Moreno L, Teira P, Croop J, Gerber N, Andre N, Aerts I Front Pediatr. 2023; 11:1183295.

PMID: 37292376 PMC: 10244735. DOI: 10.3389/fped.2023.1183295.

A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA).

Cortesi L, Venturelli M, Cortesi G, Caggia F, Toss A, Barbieri E ESMO Open. 2023; 8(2):101207.

PMID: 37028000 PMC: 10163155. DOI: 10.1016/j.esmoop.2023.101207.

Radiopharmaceuticals as Novel Immune System Tracers.

Ridge N, Rajkumar-Calkins A, Dudzinski S, Kirschner A, Newman N Adv Radiat Oncol. 2022; 7(5):100936.

PMID: 36148374 PMC: 9486425. DOI: 10.1016/j.adro.2022.100936.

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.

Chesney J, Ribas A, Long G, Kirkwood J, Dummer R, Puzanov I J Clin Oncol. 2022; 41(3):528-540.

PMID: 35998300 PMC: 9870217. DOI: 10.1200/JCO.22.00343.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Lynch T, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R . Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012; 30(17):2046-54. DOI: 10.1200/JCO.2011.38.4032. View

ODay S, Maio M, Chiarion-Sileni V, Gajewski T, Pehamberger H, Bondarenko I . Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010; 21(8):1712-1717. DOI: 10.1093/annonc/mdq013. View

Nishino M, Jagannathan J, Ramaiya N, Van Den Abbeele A . Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010; 195(2):281-9. DOI: 10.2214/AJR.09.4110. View

Nishino M, Jagannathan J, Krajewski K, ORegan K, Hatabu H, Shapiro G . Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012; 198(4):737-45. PMC: 3369700. DOI: 10.2214/AJR.11.7483. View

Zacharia T, Saini S, Halpern E, Sumner J . CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. AJR Am J Roentgenol. 2006; 186(4):1067-70. DOI: 10.2214/AJR.05.0038. View

Erasmus J, Gladish G, Broemeling L, Sabloff B, Truong M, Herbst R . Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003; 21(13):2574-82. DOI: 10.1200/JCO.2003.01.144. View

Wolchok J, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L . Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2009; 11(2):155-64. DOI: 10.1016/S1470-2045(09)70334-1. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

10.

Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya N, Hodi F . Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013; 19(14):3936-43. PMC: 3740724. DOI: 10.1158/1078-0432.CCR-13-0895. View

11.

Lin L . A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989; 45(1):255-68. View

12.

Nishino M, Cardarella S, Jackman D, Ramaiya N, Rabin M, Hatabu H . RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol. 2013; 201(1):W64-71. PMC: 3731976. DOI: 10.2214/AJR.12.9668. View

13.

Hodi F, Butler M, Oble D, Seiden M, Haluska F, Kruse A . Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008; 105(8):3005-10. PMC: 2268575. DOI: 10.1073/pnas.0712237105. View

14.

Nishino M, Jackman D, Hatabu H, Yeap B, Cioffredi L, Yap J . New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010; 195(3):W221-8. PMC: 3130298. DOI: 10.2214/AJR.09.3928. View

15.

Nishino M, Guo M, Jackman D, DiPiro P, Yap J, Ho T . CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2010; 18(1):54-62. PMC: 3129593. DOI: 10.1016/j.acra.2010.08.021. View

16.

Sun J, Ahn M, Park M, Yi J, Kim T, Chung M . Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2009; 69(1):105-9. DOI: 10.1016/j.lungcan.2009.09.014. View

17.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

18.

Weber J, Thompson J, Hamid O, Minor D, Amin A, Ron I . A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15(17):5591-8. DOI: 10.1158/1078-0432.CCR-09-1024. View

19.

Hodi F, Mihm M, Soiffer R, Haluska F, Butler M, Seiden M . Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003; 100(8):4712-7. PMC: 153621. DOI: 10.1073/pnas.0830997100. View

20.

Zhao B, James L, Moskowitz C, Guo P, Ginsberg M, Lefkowitz R . Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009; 252(1):263-72. PMC: 2797680. DOI: 10.1148/radiol.2522081593. View